What is the clinical evidence from this study?

Study design: Cohort. Population: Cardiovascular disease risk (n=2901). Intervention: Elevated peripheral levels of HGF, PAPPA, and SPON1 (≥90th centile) vs. Levels <90th centile. Primary outcome: Major adverse cardiovascular events (myocardial infarction, ischemic stroke, peripheral artery disease or revascularization procedures) (HR 3.16, 95% CI 1.55-6.45, p=0.002).

April 12, 2023Open Access

Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events

Q: What are the key findings of this study?

A peripheral blood inflammatory protein biosignature consisting of elevated HGF, PAPPA, and SPON1 was associated with a significantly increased risk of future cardiovascular events (HR 3.16).

View Full Paper

Ask AI

Bookmark

Key result

A peripheral blood inflammatory protein biosignature consisting of elevated HGF, PAPPA, and SPON1 was associated with a significantly increased risk of future cardiovascular events (HR 3.16).

Why the study?

The study investigated variation between local coronary and remote peripheral blood levels of atherosclerosis-associated proteins using the Liquid Biopsy System and examined how this relates to cardiovascular risk assessment.

Does a peripheral inflammatory protein biosignature (elevated HGF, PAPPA, and SPON1) predict major adverse cardiovascular events and mortality in patients with cardiovascular risk factors or COVID-19?

Population

28 patients undergoing coronary intervention plus reference cardiovascular and COVID-19 cohorts and healthy controls

Comparison

Local coronary vs peripheral blood levels, and presence vs absence of identified protein biosignature

Design

Biomarker study using samples from a proof-of-concept trial and reference cohorts

Authors

DPDiane ProudfootBabraham Institute BGBruna GigantePreventive Cardiology NWNick E.J. WestInterventional Cardiology

Discussion

Member takes

Implication

Should not yet change practice; hypothesis-generating for inflammatory biosignatures in CV risk prediction.

Study Design

Type

Cohort (n=2,901)

Multicenter

Yes

Structured PICO

Population

2,901 participants with at least 3 established cardiovascular risk factors followed for 3 years to assess the association of a novel inflammatory protein biosignature with major adverse cardiovascular events.

Exposure

Presence of a peripheral inflammatory protein biosignature (elevated levels >90th centile of HGF, PAPPA, and SPON1)

Comparator

Absence of the biosignature (levels <90th centile)

Outcome

Major adverse cardiovascular events (MACE) and mortalitycomposite

Main Result

Hazard Ratio: 3.16 (95% CI 1.55–6.45)

Absolute Event Rate: 20.5% vs 5.7%

p-value: p=0.002

Limitations

Small number of patients identified with the biosignature in the reference cohorts
Retrospective analysis of previously collected cohort data

Cite This Study

Proudfoot et al. (2023) conducted a cohort in Cardiovascular disease risk (n=2,901). Elevated peripheral levels of HGF, PAPPA, and SPON1 (≥90th centile) vs. Levels <90th centile was evaluated on Major adverse cardiovascular events (myocardial infarction, ischemic stroke, peripheral artery disease or revascularization procedures) (HR 3.16, 95% CI 1.55-6.45, p=0.002). A peripheral blood inflammatory protein biosignature consisting of elevated HGF, PAPPA, and SPON1 was associated with a significantly increased risk of future cardiovascular events (HR 3.16).

synapsesocial.com/papers/6a6f342b78a11c550e08e326 https://doi.org/10.1101/2023.04.06.23288168

View Full Paper

Ask AI

Bookmark

Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events

Discussion

Member takes

Implication

Study Design

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider